Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome

Shinichi Wakabayashi, Hideki Kitahara, Takeshi Nishi, Kazumasa Sugimoto, Takashi Nakayama, Yoshihide Fujimoto, Noritaka Ariyoshi, Yoshio Kobayashi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The PRASFIT-ACS study showed the antiplatelet effect 2–4 h after prasugrel loading. However, there is little information about the antiplatelet effect <2 h after prasugrel loading dose, especially in patients with acute coronary syndrome (ACS). There had not been any comparison between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS). Fifty patients with ACS (15 with STEMI and 35 with NSTE-ACS) were enrolled. They received a 20-mg prasugrel loading dose followed by a maintenance dose of 3.75 mg. Platelet reactivity [P2Y12 reaction units (PRU)] was evaluated by the VerifyNow assay at baseline, 30 min, 1, 2, 4, and 6 h, 1 week under prasugrel, and at 1 month after switching to clopidogrel. The primary end point was the change of PRU compared to the baseline. Furthermore, PRU after prasugrel loading between STEMI and NSTE-ACS was compared. A significant reduction in PRU from baseline was observed at ≥2 h after administration of prasugrel. In STEMI patients, a significant reduction in PRU was observed at 4 h after prasugrel loading. STEMI patients had higher PRU compared to NSTE-ACS patients at 2, 4, and 6 h after prasugrel loading. Utilizing >208 PRU as a cutoff value, STEMI patients had a higher prevalence of high on-treatment platelet reactivity at 2–6 h and 1 week after loading. Rapid antiplatelet effect is not achieved by low-dose prasugrel loading in STEMI patients. Platelet inhibition occurs earlier in NSTE-ACS patients, although it takes ≥2 h after loading in the majority of patients.

Original languageEnglish
Pages (from-to)239-246
Number of pages8
JournalCardiovascular Intervention and Therapeutics
Volume33
Issue number3
DOIs
Publication statusPublished - Jul 1 2018
Externally publishedYes

Fingerprint

Acute Coronary Syndrome
Blood Platelets
Prasugrel Hydrochloride
ST Elevation Myocardial Infarction
Therapeutics

Keywords

  • Percutaneous coronary intervention
  • Platelet resistance
  • Prasugrel
  • VerifyNow

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. / Wakabayashi, Shinichi; Kitahara, Hideki; Nishi, Takeshi; Sugimoto, Kazumasa; Nakayama, Takashi; Fujimoto, Yoshihide; Ariyoshi, Noritaka; Kobayashi, Yoshio.

In: Cardiovascular Intervention and Therapeutics, Vol. 33, No. 3, 01.07.2018, p. 239-246.

Research output: Contribution to journalArticle

Wakabayashi, Shinichi ; Kitahara, Hideki ; Nishi, Takeshi ; Sugimoto, Kazumasa ; Nakayama, Takashi ; Fujimoto, Yoshihide ; Ariyoshi, Noritaka ; Kobayashi, Yoshio. / Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. In: Cardiovascular Intervention and Therapeutics. 2018 ; Vol. 33, No. 3. pp. 239-246.
@article{5f9be1b75bc34a7089c3da7faf1456ad,
title = "Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome",
abstract = "The PRASFIT-ACS study showed the antiplatelet effect 2–4 h after prasugrel loading. However, there is little information about the antiplatelet effect <2 h after prasugrel loading dose, especially in patients with acute coronary syndrome (ACS). There had not been any comparison between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS). Fifty patients with ACS (15 with STEMI and 35 with NSTE-ACS) were enrolled. They received a 20-mg prasugrel loading dose followed by a maintenance dose of 3.75 mg. Platelet reactivity [P2Y12 reaction units (PRU)] was evaluated by the VerifyNow assay at baseline, 30 min, 1, 2, 4, and 6 h, 1 week under prasugrel, and at 1 month after switching to clopidogrel. The primary end point was the change of PRU compared to the baseline. Furthermore, PRU after prasugrel loading between STEMI and NSTE-ACS was compared. A significant reduction in PRU from baseline was observed at ≥2 h after administration of prasugrel. In STEMI patients, a significant reduction in PRU was observed at 4 h after prasugrel loading. STEMI patients had higher PRU compared to NSTE-ACS patients at 2, 4, and 6 h after prasugrel loading. Utilizing >208 PRU as a cutoff value, STEMI patients had a higher prevalence of high on-treatment platelet reactivity at 2–6 h and 1 week after loading. Rapid antiplatelet effect is not achieved by low-dose prasugrel loading in STEMI patients. Platelet inhibition occurs earlier in NSTE-ACS patients, although it takes ≥2 h after loading in the majority of patients.",
keywords = "Percutaneous coronary intervention, Platelet resistance, Prasugrel, VerifyNow",
author = "Shinichi Wakabayashi and Hideki Kitahara and Takeshi Nishi and Kazumasa Sugimoto and Takashi Nakayama and Yoshihide Fujimoto and Noritaka Ariyoshi and Yoshio Kobayashi",
year = "2018",
month = "7",
day = "1",
doi = "10.1007/s12928-017-0475-8",
language = "English",
volume = "33",
pages = "239--246",
journal = "Cardiovascular Intervention and Therapeutics",
issn = "1868-4300",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome

AU - Wakabayashi, Shinichi

AU - Kitahara, Hideki

AU - Nishi, Takeshi

AU - Sugimoto, Kazumasa

AU - Nakayama, Takashi

AU - Fujimoto, Yoshihide

AU - Ariyoshi, Noritaka

AU - Kobayashi, Yoshio

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The PRASFIT-ACS study showed the antiplatelet effect 2–4 h after prasugrel loading. However, there is little information about the antiplatelet effect <2 h after prasugrel loading dose, especially in patients with acute coronary syndrome (ACS). There had not been any comparison between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS). Fifty patients with ACS (15 with STEMI and 35 with NSTE-ACS) were enrolled. They received a 20-mg prasugrel loading dose followed by a maintenance dose of 3.75 mg. Platelet reactivity [P2Y12 reaction units (PRU)] was evaluated by the VerifyNow assay at baseline, 30 min, 1, 2, 4, and 6 h, 1 week under prasugrel, and at 1 month after switching to clopidogrel. The primary end point was the change of PRU compared to the baseline. Furthermore, PRU after prasugrel loading between STEMI and NSTE-ACS was compared. A significant reduction in PRU from baseline was observed at ≥2 h after administration of prasugrel. In STEMI patients, a significant reduction in PRU was observed at 4 h after prasugrel loading. STEMI patients had higher PRU compared to NSTE-ACS patients at 2, 4, and 6 h after prasugrel loading. Utilizing >208 PRU as a cutoff value, STEMI patients had a higher prevalence of high on-treatment platelet reactivity at 2–6 h and 1 week after loading. Rapid antiplatelet effect is not achieved by low-dose prasugrel loading in STEMI patients. Platelet inhibition occurs earlier in NSTE-ACS patients, although it takes ≥2 h after loading in the majority of patients.

AB - The PRASFIT-ACS study showed the antiplatelet effect 2–4 h after prasugrel loading. However, there is little information about the antiplatelet effect <2 h after prasugrel loading dose, especially in patients with acute coronary syndrome (ACS). There had not been any comparison between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS). Fifty patients with ACS (15 with STEMI and 35 with NSTE-ACS) were enrolled. They received a 20-mg prasugrel loading dose followed by a maintenance dose of 3.75 mg. Platelet reactivity [P2Y12 reaction units (PRU)] was evaluated by the VerifyNow assay at baseline, 30 min, 1, 2, 4, and 6 h, 1 week under prasugrel, and at 1 month after switching to clopidogrel. The primary end point was the change of PRU compared to the baseline. Furthermore, PRU after prasugrel loading between STEMI and NSTE-ACS was compared. A significant reduction in PRU from baseline was observed at ≥2 h after administration of prasugrel. In STEMI patients, a significant reduction in PRU was observed at 4 h after prasugrel loading. STEMI patients had higher PRU compared to NSTE-ACS patients at 2, 4, and 6 h after prasugrel loading. Utilizing >208 PRU as a cutoff value, STEMI patients had a higher prevalence of high on-treatment platelet reactivity at 2–6 h and 1 week after loading. Rapid antiplatelet effect is not achieved by low-dose prasugrel loading in STEMI patients. Platelet inhibition occurs earlier in NSTE-ACS patients, although it takes ≥2 h after loading in the majority of patients.

KW - Percutaneous coronary intervention

KW - Platelet resistance

KW - Prasugrel

KW - VerifyNow

UR - http://www.scopus.com/inward/record.url?scp=85048812465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048812465&partnerID=8YFLogxK

U2 - 10.1007/s12928-017-0475-8

DO - 10.1007/s12928-017-0475-8

M3 - Article

VL - 33

SP - 239

EP - 246

JO - Cardiovascular Intervention and Therapeutics

JF - Cardiovascular Intervention and Therapeutics

SN - 1868-4300

IS - 3

ER -